CJC-1295 5mg + Ipamorelin 5mg

CJC-1295 5mg + Ipamorelin 5mg is a synergistic peptide blend designed for research and laboratory use. This dual-peptide formulation combines a modified growth-hormone-releasing hormone analogue with a selective growth-hormone secretagogue, delivering complementary mechanisms of action for advanced GH-axis research. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions exploring peptide-based studies. Store in a cool, dry place away from direct light. For research purposes only.

Specifications: Active Ingredients: CJC-1295 (no DAC) and Ipamorelin Concentration: 5mg CJC-1295 + 5mg Ipamorelin per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting peptide research and development studies.

Molecular Formula CJC-1295: C₁₅₂H₂₅₂N₄₂O₄₂S Molecular Weight: 3,367.97 g/mol Sequence Classification: 29-amino acid GHRH analogue with drug affinity complex modifications Purity Analysis: ≥98% by HPLC Molecular Formula Ipamorelin: C₃₈H₄₉N₉O₅ Molecular Weight: 711.87 g/mol Sequence Classification: 5-amino acid selective GH secretagogue and ghrelin mimetic Purity Analysis: ≥98% by HPLC This molecular data supports advanced research into growth-hormone axis regulation, pulsatile GH release mechanisms, and receptor interaction studies.

Storage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or appropriate diluent, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. CJC-1295 Pharmacokinetics and Prolonged GH Release
   Jetté L, et al. (2005). hGRF1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: A Comparison of the Pharmacokinetics and Pharmacodynamics of Eight Bioconjugates. Journal of Pharmacology and Experimental Therapeutics, 317(3), 1228–1237. https://doi.org/10.1124/jpet.105.089755
   Characterises the extended half-life and sustained GH-releasing activity of CJC-1295 analogues via albumin-binding modifications, establishing the pharmacokinetic basis for prolonged GHRH receptor activation.
2. CJC-1295 Clinical Dose–Response in Healthy Adults
   Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
   Demonstrates dose-dependent, sustained elevation of GH and IGF-1 following CJC-1295 administration, with a half-life of 5–8 days, supporting its use as a long-acting GHRH analogue in research models.
3. Ipamorelin: Selectivity and GH Secretagogue Activity
   Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
   Establishes ipamorelin as a highly selective GH secretagogue with minimal effect on cortisol, prolactin, or ACTH, distinguishing it from earlier GHRPs and making it a preferred tool for isolated GH-axis research.
4. Synergistic GH Release: GHRH + GHS Combination
   Bowers CY, et al. (1990). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537–1545. https://doi.org/10.1210/endo-114-5-1537
   Foundational study demonstrating the synergistic amplification of GH release when GHRH analogues are combined with GH secretagogues, providing the mechanistic rationale for dual-peptide research protocols.
5. Ghrelin Receptor Signalling and GHRP Mechanisms
   Smith RG, et al. (2007). Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews, 28(3), 346–360. https://doi.org/10.1210/er.2006-0048
   Comprehensive review of GHS-R1a receptor signalling pathways activated by ipamorelin and related ghrelin mimetics, covering downstream effects on somatotroph function and GH pulse amplitude relevant to CJC-1295 + Ipamorelin combination studies.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.